Development of next generation hemagglutinin-based broadly protective influenza virus vaccines

Current Opinion in Immunology

Volumn 53, Issue , 2018, Pages 51-57

  Nachbagauer, Raffael ^a   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC HEMAGGLUTININ; CHIMERIC HEMAGGLUTININ VACCINE; COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGEN VACCINE; CONSERVED EPITOPE; CONSERVED PEPTIDE POOL VACCINE; CROSS REACTING ANTIBODY; EPITOPE; HEADLESS HEMAGGLUTININ INFLUENZA VIRUS VACCINE; HEMAGGLUTININ BASED INFLUENZA VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; RECOMBINANT ANTIGEN; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS LIKE PARTICLE VACCINE;

2009 H1N1 INFLUENZA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; CHIMERA; CONSENSUS SEQUENCE; CROSS REACTION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG MANUFACTURE; DRUG RESPONSE; DRUG TREATMENT FAILURE; EXPOSURE; HEALTH PROMOTION; HEMAGGLUTININ BASED BROADLY PROTECTIVE INFLUENZA VIRUS VACCINATION; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA VACCINATION; MATHEMATICAL ANALYSIS; MORTALITY; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC INFLUENZA; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; REVACCINATION; REVIEW; SEASONAL INFLUENZA; SEQUENCE ANALYSIS; SPANISH INFLUENZA; VACCINE IMMUNOGENICITY; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS LIKE AGENT; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; ANIMAL; IMMUNOLOGY; METABOLISM; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRUS INFECTION; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 85045581646     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2018.04.001     Document Type: Review

References (53)

1. Pappas, G., Kiriaze, I.J., Falagas, M.E., Insights into infectious disease in the era of Hippocrates. Int J Infect Dis 12 (2008), 347–350.
2. WHO, Influenza (Seasonal) Fact Sheet 211. 2018 http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed 24.01.18).
3. Molinari, N.A., Ortega-Sanchez, I.R., Messonnier, M.L., Thompson, W.W., Wortley, P.M., Weintraub, E., Bridges, C.B., The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25 (2007), 5086–5096.
4. Johnson, N.P., Mueller, J., Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med 76 (2002), 105–115.
5. Dawood, F.S., Iuliano, A.D., Reed, C., Meltzer, M.I., Shay, D.K., Cheng, P.Y., Bandaranayake, D., Breiman, R.F., Brooks, W.A., Buchy, P., Feikin, D.R., Fowler, K.B., Gordon, A., Hien, N.T., Horby, P., Huang, Q.S., Katz, M.A., Krishnan, A., Lal, R., Montgomery, J.M., Molbak, K., Pebody, R., Presanis, A.M., Razuri, H., Steens, A., Tinoco, Y.O., Wallinga, J., Yu, H., Vong, S., Bresee, J., Widdowson, M.A., Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12 (2012), 687–695.
6. WHO, 2015-06-21 03:35:48 2015. WHO | Pandemic (H1N1) 2009 — Update 67, on World Health Organization (WHO). 2018 http://www.who.int/csr/don/2009_09_25/en/ (accessed 24.01.18).
7. CDC, CDC Novel H1N1 Flu | The 2009 H1N1 Pandemic: Summary Highlights. 2016, April 2009–April 2010, on Centers for Disease Control and Prevention (CDC) http://www.cdc.gov/h1n1flu/cdcresponse.htm (accessed 24.01.18).
8. Huber, V.C., Influenza vaccines: from whole virus preparations to recombinant protein technology. Expert Rev Vaccines 13 (2014), 31–42.
9. Smith, W., Andrewes, C.H., Laidlaw, P.P., A virus obtained from influenza patients. Lancet 2 (1933), 66–68.
10. Francis, T. Jr., A new type of virus from epidemic influenza. Science 92 (1940), 405–408.
11. Sartwell, P.E., Long, A.P., The Army experience with influenza, 1946–1947; epidemiological aspects. Am J Hyg 47 (1948), 135–141.
12. Hannoun, C., The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 12 (2013), 1085–1094.
13. Francis, T. Jr., Salk, J.E., Quilligan, J.J. Jr., Experience with vaccination against influenza in the spring of 1947; a preliminary report. Am J Public Health Nations Health 37 (1947), 1013–1016.
14. Payne, A.M., The influenza programme of WHO. Bull World Health Organ 8 (1953), 755–774.
15. WHO, WHO Recommendations on the Composition of Influenza Virus Vaccines. 2018 http://www.who.int/influenza/vaccines/virus/recommendations/en/ (accessed 24.01.18).
16. Practices PHSACoI., Influenza vaccine: preliminary statement. Recommendation of the Public Health Service Advisory Committee on Immunization Practices. Ann Intern Med 89 (1978), 373–374.
17. Graves, P.N., Schulman, J.L., Young, J.F., Palese, P., Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 126 (1983), 106–116.
18. Okuno, Y., Isegawa, Y., Sasao, F., Ueda, S., A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67 (1993), 2552–2558.
19. GlaxoSmithKline, A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Investigational Supra-Seasonal Universal Influenza Vaccines — Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years. 2017 https://clinicaltrials.gov/show/NCT03275389 (accessed 07.09.17).
20. PATH, Safety and Immunogenicity of a Live-Attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine. 2017 https://clinicaltrials.gov/show/NCT03300050 (accessed 03.10.17).
21. Shaw, M.L.P.P., Fields Virology. edn 6, 2013, LWW, 1151–1185.
22. Moody, M.A., Zhang, R., Walter, E.B., Woods, C.W., Ginsburg, G.S., McClain, M.T., Denny, T.N., Chen, X., Munshaw, S., Marshall, D.J., Whitesides, J.F., Drinker, M.S., Amos, J.D., Gurley, T.C., Eudailey, J.A., Foulger, A., DeRosa, K.R., Parks, R., Meyerhoff, R.R., Yu, J.S., Kozink, D.M., Barefoot, B.E., Ramsburg, E.A., Khurana, S., Golding, H., Vandergrift, N.A., Alam, S.M., Tomaras, G.D., Kepler, T.B., Kelsoe, G., Liao, H.X., Haynes, B.F., H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE, 6, 2011, e25797.
23. Wrammert, J., Smith, K., Miller, J., Langley, W.A., Kokko, K., Larsen, C., Zheng, N.Y., Mays, I., Garman, L., Helms, C., James, J., Air, G.M., Capra, J.D., Ahmed, R., Wilson, P.C., Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453 (2008), 667–671.
24. Doud, M.B., Bloom, J.D., Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. Viruses, 8, 2016.
25. Dreyfus, C., Laursen, N.S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D.C., Lee, J.H., Metlagel, Z., Bujny, M.V., Jongeneelen, M., van der Vlugt, R., Lamrani, M., Korse, H.J., Geelen, E., Sahin, O., Sieuwerts, M., Brakenhoff, J.P., Vogels, R., Li, O.T., Poon, L.L., Peiris, M., Koudstaal, W., Ward, A.B., Wilson, I.A., Goudsmit, J., Friesen, R.H., Highly conserved protective epitopes on influenza B viruses. Science 337 (2012), 1343–1348.
26. Krause, J.C., Tsibane, T., Tumpey, T.M., Huffman, C.J., Basler, C.F., Crowe, J.E. Jr., A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85 (2011), 10905–10908.
27. Whittle, J.R., Zhang, R., Khurana, S., King, L.R., Manischewitz, J., Golding, H., Dormitzer, P.R., Haynes, B.F., Walter, E.B., Moody, M.A., Kepler, T.B., Liao, H.X., Harrison, S.C., Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108 (2011), 14216–14221.
28. Ellebedy, A.H., Krammer, F., Li, G.M., Miller, M.S., Chiu, C., Wrammert, J., Chang, C.Y., Davis, C.W., McCausland, M., Elbein, R., Edupuganti, S., Spearman, P., Andrews, S.F., Wilson, P.C., Garcia-Sastre, A., Mulligan, M.J., Mehta, A.K., Palese, P., Ahmed, R., Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 111 (2014), 13133–13138.
29. Nachbagauer, R., Wohlbold, T.J., Hirsh, A., Hai, R., Sjursen, H., Palese, P., Cox, R.J., Krammer, F., Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 88 (2014), 13260–13268.
30. Hai, R., Krammer, F., Tan, G.S., Pica, N., Eggink, D., Maamary, J., Margine, I., Albrecht, R.A., Palese, P., Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 86 (2012), 5774–5781.
31. Nachbagauer, R., Miller, M.S., Hai, R., Ryder, A.B., Rose, J.K., Palese, P., Garcia-Sastre, A., Krammer, F., Albrecht, R.A., Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. J Virol 90 (2015), 3268–3273.
32. Krammer, F., Pica, N., Hai, R., Margine, I., Palese, P., Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87 (2013), 6542–6550.
33. Nachbagauer, R., Kinzler, D., Choi, A., Hirsh, A., Beaulieu, E., Lecrenier, N., Innis, B.L., Palese, P., Mallett, C.P., Krammer, F., A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. NPJ Vaccines, 1, 2016.
34. Nachbagauer, R., Liu, W.C., Choi, A., Wohlbold, T.J., Atlas, T., Rajendran, M., Solorzano, A., Berlanda-Scorza, F., Garcia-Sastre, A., Palese, P., Albrecht, R.A., Krammer, F., A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines, 2, 2017, 26 In this study, a live-attenuated influenza virus vaccine that expressed a chimeric hemagglutinin followed by an inactivated booster vaccination was tested in ferrets. The vaccination approach successfully reduced viral lung titers in vaccinated animals.
35. Bommakanti, G., Citron, M.P., Hepler, R.W., Callahan, C., Heidecker, G.J., Najar, T.A., Lu, X., Joyce, J.G., Shiver, J.W., Casimiro, D.R., ter Meulen, J., Liang, X., Varadarajan, R., Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 107 (2010), 13701–13706.
36. Wohlbold, T.J., Nachbagauer, R., Margine, I., Tan, G.S., Hirsh, A., Krammer, F., Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine 33 (2015), 3314–3321.
37. Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M.V., Zhu, X., Hoffman, R.M., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J., de Man, M., Ding, Z., Apetri, A., Kukrer, B., Sneekes-Vriese, E., Tomkiewicz, D., Laursen, N.S., Lee, P.S., Zakrzewska, A., Dekking, L., Tolboom, J., Tettero, L., van Meerten, S., Yu, W., Koudstaal, W., Goudsmit, J., Ward, A.B., Meijberg, W., Wilson, I.A., Radosevic, K., A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349 (2015), 1301–1306 The manuscript by Impagliazzo et al. describes a hemagglutinin stem-only vaccine approach. Their engineered H1 stem antigen was shown to be conformationally stable and elicited protective immunity in mice and non-human primates.
38. Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.J., Kanekiyo, M., Kong, W.P., Gallagher, J.R., Wang, L., Zhang, Y., Joyce, M.G., Lingwood, D., Moin, S.M., Andersen, H., Okuno, Y., Rao, S.S., Harris, A.K., Kwong, P.D., Mascola, J.R., Nabel, G.J., Graham, B.S., Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21 (2015), 1065–1070 In this study, researchers described an approach that uses stabilized H1 stem-only constructs linked to ferritin nanoparticles as vaccines. Their constructs conferred complete protection in mice and partial protection in ferrets against a lethal H5N1 challenge.
39. Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., Garcia-Sastre, A., Palese, P., Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio, 1, 2010.
40. Sutton, T.C., Chakraborty, S., Mallajosyula, V.V.A., Lamirande, E.W., Ganti, K., Bock, K.W., Moore, I.N., Varadarajan, R., Subbarao, K., Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines. NPJ Vaccines, 2, 2017, 35 In this study hemagglutinin stem-only constructs were tested for group 2. The design of stable group 2 antigens has long posed an even more difficult challenge than for group 1 antigens. Mice vaccinated with these constructs were protected against homologous strains and partially protected against heterologous strains.
41. Mallajosyula, V.V., Citron, M., Ferrara, F., Lu, X., Callahan, C., Heidecker, G.J., Sarma, S.P., Flynn, J.A., Temperton, N.J., Liang, X., Varadarajan, R., Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A 111 (2014), E2514–E2523.
42. Valkenburg, S.A., Mallajosyula, V.V., Li, O.T., Chin, A.W., Carnell, G., Temperton, N., Varadarajan, R., Poon, L.L., Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci Rep, 6, 2016, 22666.
43. Giles, B.M., Ross, T.M., A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29 (2011), 3043–3054.
44. Crevar, C.J., Carter, D.M., Lee, K.Y., Ross, T.M., Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades. Hum Vaccin Immunother 11 (2015), 572–583.
45. Giles, B.M., Bissel, S.J., Dealmeida, D.R., Wiley, C.A., Ross, T.M., Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol 19 (2012), 128–139.
46. Giles, B.M., Crevar, C.J., Carter, D.M., Bissel, S.J., Schultz-Cherry, S., Wiley, C.A., Ross, T.M., A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 205 (2012), 1562–1570.
47. Carter, D.M., Darby, C.A., Lefoley, B.C., Crevar, C.J., Alefantis, T., Oomen, R., Anderson, S.F., Strugnell, T., Cortes-Garcia, G., Vogel, T.U., Parrington, M., Kleanthous, H., Ross, T.M., Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol 90 (2016), 4720–4734 The manuscript by Carter et al. describes a vaccination experiment in ferrets that have been repeatedly exposed to various H1N1 influenza virus strains to mimic a pre-exposed immune system more similar to that of humans. Vaccination of these ferrets with computationally optimized broadly reactive hemagglutinin antigens (COBRA) elicited broad responses against multiple H1N1 virus strains.
48. Wong, T.M., Allen, J.D., Bebin-Blackwell, A.G., Carter, D.M., Alefantis, T., DiNapoli, J., Kleanthous, H., Ross, T.M., Computationally optimized broadly reactive hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2 influenza virus cocirculating variants. J Virol, 91, 2017.
49. Carter, D.M., Darby, C.A., Johnson, S.K., Carlock, M.A., Kirchenbaum, G.A., Allen, J.D., Vogel, T.U., Delagrave, S., DiNapoli, J., Kleanthous, H., Ross, T.M., Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets preimmune to historical H1N1 influenza viruses. J Virol, 91, 2017.
50. Schwartzman, L.M., Cathcart, A.L., Pujanauski, L.M., Qi, L., Kash, J.C., Taubenberger, J.K., An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus. MBio, 6, 2015, e01044.
51. Muller, G.M., Shapira, M., Arnon, R., Anti-influenza response achieved by immunization with a synthetic conjugate. Proc Natl Acad Sci U S A 79 (1982), 569–573.
52. Ben-Yedidia, T., Arnon, R., Epitope-based vaccine against influenza. Expert Rev Vaccines 6 (2007), 939–948.
53. NIAID, Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine. 2017 https://clinicaltrials.gov/ct2/show/NCT03058692 (accessed 23.02.17).